H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on ...

To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on ...

SEC Filings provided by EDGAR Online, Inc.

Wedbush reiterated an “outperform” rating and set a $70.00 target price on shares of Revolution Medicines in a research note on Monday, December 2nd. JPMorgan Chase & Co. upped their price ...

About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D ...

Revolution Medicines Inc (NASDAQ:RVMD) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $0.35 million, and the earnings are expected to come in ...

Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), a company specializing in biological products, has recently sold a portion of her shares in... ByInvesting ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a biotechnology company focused on developing novel therapies for cancer, has been making significant strides in its clinical pipeline, particularly in ...

1 Day RVMD 4.25% DJIA 1.39% S&P 500 1.59% Health Care/Life Sciences -0.37% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...